The new technology enables a simple way of connecting the cytsteine residues (SH) of a tumor-sensing antibody (yellow) to toxic drug molecules. The emerging linker is highly stable during blood circulation and enables therefore a safe transport to the tumor side. (picture by Barth van Rossum/FMP)
Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.
Classic chemotherapy for the treatment of cancer is based on toxic substances that are particularly effective for rapidly dividing cells. However, since healthy tissue also depends on cell division, treatment with chemotherapeutic substances is often accompanied by severe side effects. A dose sufficient to completely remove the tumor, would in many cases be too toxic to administer to a diseased person. With more modern approaches, it is now possible to transport active agents (drugs) in the body selectively to the site of action, for example by linking a drug with an antibody that can differentiate cancer cells from healthy tissue through changes on the surface of the cell. Five such Antibody Drug Conjugates (ADCs) are already on the market.
However, these ADCs lose a large part of their “toxic cargo” en route to the cancer cell. The substances (drugs) are released into the bloodstream and dangerous side effects can occur. A stable link between drug and antibody would therefore be highly desirable. This is precisely what the researchers – a team led by Professor Christian Hackenberger from the FMP and Professor Heinrich Leonhardt from the LMU Biocenter – focused on. Their results have been published in the prestigious journal, Angewandte Chemie: In two consecutive articles, the development of methods and the application of these methods to selective drug transport are presented.
The new drug transporters enable lower doses and less severe side effects
“We have developed an innovative technology that makes it possible to link native proteins and antibodies to complex molecules, such as fluorescent dyes or drugs more easily and with better stability than ever before,” reports Marc-André Kasper, a researcher in Christian Hackenberger’s group. The researchers discovered the outstanding properties of unsaturated phosphorus (V) compounds and took advantage of those. These phosphonamidates connect a desired modification – for example, a cancer-fighting agent – exclusively to the amino acid cysteine, in a protein or antibody. Since cysteine is a very rare natural occurring amino acid, the number of modifications per protein can be controlled quite effectively, which is essential for the construction of drug conjugates. In addition, phosphonamidates can easily be incorporated into complex chemical compounds. “The greatest achievement of the new method, however, is that the resulting bond is also stable during blood circulation,” says Marc-André Kasper. The ADCs that are on the market cannot achieve this.
To test the applicability on targeted drug delivery, the researchers compared their technology directly with the FDA-approved ADC, Adcetris®. The medication was re-created as precisely as possible with the same antibody and active agent, the only difference was that the innovative phosphonamidate linkage was used. When applied to blood serum, the researchers observed that their modified ADC lost significantly less active ingredient over a period of days. They also used the new technology in experiments with mice to combat Hodgkin’s lymphoma. The preparation proved to be more effective than the conventional medication. “From our results, we conclude that phosphonamidate-linked drug transporters can be administered in lower doses, and that side effects can be further reduced. Thus the technology has great potential to replace current methods in order to develop more effective and safer ADCs in the future,” says FMP group leader Christian Hackenberger.
In the next step, the research groups will continue their efforts in the development of ADCs based on phosphonamidates. Preclinical studies, which are essential for the treatment of patients, are already underway. In this regard, the promising start-up company Tubulis, which was awarded the Leibniz Start-Up Prize last year, functions as a platform for the further development to market maturity.
Learn more: Bringing cancer medication safely to its destination
The Latest on: Antibody Drug Conjugates
via Google News
The Latest on: Antibody Drug Conjugates
- Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updateon May 12, 2022 at 3:01 pm
“In the first quarter of 2022, we have made significant progress in advancing the preclinical development of SBT8230, a first-in-class antibody-drug conjugate that we believe has the potential to ...
- Talzenna-Novel Drug Combo Continues to Be Studied in Patients With Triple-Negative Breast Canceron May 12, 2022 at 11:12 am
The phase 2b portion of the trial, according to a company-issued press release, will enroll patients who have previously been treated with a Trophoblast cell surface antigen 2 (TROP2) antibody drug ...
- New Bladder Cancer Drugs: Immunotherapy and Antibody-Drug Conjugateson May 12, 2022 at 8:41 am
These two drug classes, checkpoint inhibitors and antibody-drug conjugates (ADCs), are giving patients much-improved treatment options for various stages of the disease. Checkpoint inhibitors enable ...
- Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congresson May 12, 2022 at 7:02 am
Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, will be presented at the European ...
- Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developmentson May 11, 2022 at 5:02 am
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active ...
- ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conferenceon May 10, 2022 at 1:30 pm
ImmunoGen, Inc. IMGN, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will present at ...
- Antibody Drug Conjugates Contract Manufacturing Market Will Hit Big Revenues In Future | Cambrex, ReciPharm, ThermoFisher and moreon May 10, 2022 at 3:49 am
Comprehensive analyzes of the fastest-growing Antibody Drug Conjugates Contract Manufacturing Market provide insights that help stakeholders identify opportunities and challenges. The markets of 2022 ...
- ADC Technology: A Premier Institution of Antibody-Drug Conjugates Developmenton May 5, 2022 at 6:07 pm
ADC Technology releases a wide range of one-stop services related to ADC development such as antibody selection/modification, ADC payload and linker development, ADC conjugation, and ADC characterizat ...
- Antibody Drug Conjugates Market Size Worth USD 44.45 Bn By 2027on May 5, 2022 at 4:30 am
As per our research report, the global antibody drug conjugates market size was valued at USD 14.72 billion in 2022 and this value is further estimated to be growing at a CAGR of 24.74% from 2022 to ...
- Tackling Antibody-Drug Conjugate Manufacturing Challengeson May 4, 2022 at 10:06 am
Antibody-Drug Conjugates (ADCs) are an exciting and emerging class of biopharmaceuticals with applications in cancer. GEN talks to Yunus Saricay, PhD, an R&D specialist at Byondis B.V., about the ...
via Bing News